Metacrine Public
Metacrine is a clinical-stage biopharmaceutical company that specializes in developing innovative drugs to treat liver and gastrointestinal diseases. Their main focus is on the farnesoid X receptor (FXR) program, which targets multiple liver and GI diseases. In addition to the FXR program, Metacrine also explores other drug targets through their internal drug discovery and development capabilities. Their goal is to pioneer differentiated therapies for patients with GI and liver diseases. Recently, the FXR Program has been acquired by Organovo. For more information, please visit www.organovo.com.
Last Funding Type:
Debt Financing
Last Funding Date:
2019
Funding Status:
IPO
Headquarters:
San Diego, California, United States
Industry:
PharmTech
Investor Type:
IPO
Estimated Revenue:
$10M to $50M
Technology:
Immunotherapy
Total Funding:
173000000
Investors Number:
14
Employee Number:
11-50
Founded Date:
2015